Our findings demonstrated that the suppression of NLRP3 inflammasome activation by an orally available small molecule inhibitor leads to the alleviation of the hepatic steatosis symptoms associated with NAFLD induced by a high-fat diet. The gene discussed is NLRP3; the disease is metabolic dysfunction-associated steatotic liver disease.